Who are V920 Consistency Lot A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hepatitis B recombinant vaccine, Engerix B, EngerixB, GlaxoSmithKline Vaccines, Recombinant Human Papillomavirus Nonavalent Vaccine, RECOMBIVAX HB™, HPV9v.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/v920-consistency-lot-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

V920 Consistency Lot A — Competitive Intelligence Brief

V920 Consistency Lot A (V920 Consistency Lot A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant vaccine Varicella-zoster virus (VZV) glycoproteins Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

V920 Consistency Lot A (V920 Consistency Lot A) — Merck Sharp & Dohme LLC. V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
V920 Consistency Lot A TARGET	V920 Consistency Lot A	Merck Sharp & Dohme LLC	phase 3	Recombinant vaccine	Varicella-zoster virus (VZV) glycoproteins
Hepatitis B recombinant vaccine	Hepatitis B recombinant vaccine	Pontificia Universidad Catolica de Chile	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Engerix B	Engerix B	Crucell Holland BV	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
EngerixB, GlaxoSmithKline Vaccines	EngerixB, GlaxoSmithKline Vaccines	University of British Columbia	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Recombinant Human Papillomavirus Nonavalent Vaccine	Recombinant Human Papillomavirus Nonavalent Vaccine	National Cancer Institute (NCI)	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
RECOMBIVAX HB™	RECOMBIVAX HB™	Merck Sharp & Dohme LLC	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
HPV9v	HPV9v	Fundacion SEIMC-GESIDA	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant vaccine class)

GlaxoSmithKline · 5 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Crucell Holland BV · 2 drugs in this class
Shanghai Institute Of Biological Products · 2 drugs in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
University of British Columbia · 1 drug in this class
Fundacion SEIMC-GESIDA · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). V920 Consistency Lot A — Competitive Intelligence Brief. https://druglandscape.com/ci/v920-consistency-lot-a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab